Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying the stock. We monitor 13F filings and institutional buying patterns because large investors often have superior information.
This analysis evaluates Biogen Inc.’s (NASDAQ: BIIB) recently announced definitive licensing agreement with TJ Biopharma for Greater China rights to experimental antibody felzartamab, a key late-stage asset in the firm’s immunology pipeline. The $850 million total potential deal unlocks full global
Biogen Inc. (BIIB) - Secures Exclusive Global Felzartamab Rights via Greater China Licensing Deal, Shares Rally - Beat Estimates
BIIB - Stock Analysis
3404 Comments
1348 Likes
1
Jenalys
Engaged Reader
2 hours ago
Real-time US stock alerts and notifications ensuring you never miss important price movements or market opportunities that could impact your portfolio. Our customizable alert system lets you monitor specific stocks, sectors, or market conditions that matter most to your investment strategy. We provide price alerts, volume alerts, news alerts, and technical pattern alerts for comprehensive market coverage. Never miss a trading opportunity again with our comprehensive alert system designed for active and passive investors.
👍 156
Reply
2
Shallon
Power User
5 hours ago
I bow down to your genius. 🙇♂️
👍 124
Reply
3
Zagan
Insight Reader
1 day ago
Traders are watching for confirmation above key resistance points.
👍 133
Reply
4
Sevin
Active Reader
1 day ago
Are you secretly training with ninjas? 🥷
👍 272
Reply
5
Wilie
Returning User
2 days ago
I know there are others out there.
👍 58
Reply
© 2026 Market Analysis. All data is for informational purposes only.